Core Viewpoint - The incidence of acute pulmonary embolism (PE) is rising, necessitating increased awareness and preventive measures among high-risk populations [2][4]. Group 1: Incidence and Risk Factors - The global incidence of pulmonary embolism ranges from 11.7 to 131.9 per 100,000, with China's hospitalization rate increasing from 1.2 per 100,000 in 2007 to 14.2 per 100,000 in 2021, exceeding 200,000 cases [2]. - High-risk groups include the elderly, especially those over 80, who have a significantly higher risk compared to those under 50 [3]. - Other high-risk populations include pregnant women, patients undergoing surgery, those with malignancies, cardiovascular diseases, chronic obstructive pulmonary disease, kidney syndrome, obesity, smokers, and individuals who remain sedentary during long flights [4]. Group 2: Symptoms and Diagnosis - Symptoms of acute pulmonary embolism lack specificity, making it prone to misdiagnosis; common symptoms include activity-related shortness of breath, chest pain, and syncope [5]. - The classic triad of symptoms (chest pain, hemoptysis, and dyspnea) occurs in less than 20% of cases, highlighting the need for vigilance in recognizing atypical presentations [5]. - Diagnosis involves a two-step process: initial screening using ECG and echocardiography, followed by confirmatory imaging such as CT pulmonary angiography [6]. Group 3: Treatment and Management - Treatment strategies are tailored based on the severity of the condition, with high-risk patients requiring aggressive intervention and lower-risk patients primarily receiving anticoagulation therapy [7]. - Anticoagulation is the cornerstone of treatment, while thrombolysis is reserved for high-risk patients experiencing cardiac arrest or obstructive shock [7]. - Patients must adhere to prescribed medication regimens and undergo regular monitoring to prevent complications, including chronic thromboembolic pulmonary hypertension [8]. Group 4: Prevention and Prognosis - Prevention strategies include avoiding prolonged immobility, engaging in regular movement during long travels, and using compression stockings for high-risk individuals [8]. - The overall prognosis for pulmonary embolism patients is improving, but timely treatment and adherence to management plans are crucial to prevent severe outcomes [8].

Core Viewpoint - Merck (MRK.US) shares rose over 4% to $96.97 following FDA approval of its pulmonary hypertension therapy, Winrevair, which achieved primary endpoints in patients with pulmonary hypertension [1] Group 1: Drug Approval and Efficacy - The FDA approved Winrevair for treating pulmonary hypertension, a condition characterized by elevated blood pressure in the pulmonary blood vessels [1] - Data from the 24-week Phase 2 CADENCE study indicated that Winrevair significantly reduced pulmonary vascular resistance, meeting the trial's primary endpoint with both statistical and clinical significance [1] - The study aimed to evaluate the efficacy of the injection compared to a placebo in adult patients with pre-capillary and post-capillary pulmonary hypertension due to heart failure with preserved ejection fraction (HFpEF) [1] Group 2: Safety and Future Plans - The company reported that Winrevair's tolerability aligns with established safety profiles [1] - Merck plans to present the study results at future medical conferences and continue advancing the drug's late-stage projects in CpcPH caused by HFpEF [1]

Group 1 - The core issue of pulmonary arterial hypertension (PAH) is its high misdiagnosis rate and subtle symptoms, making it a "silent killer" [1][2] - PAH is characterized by increased pulmonary vascular resistance and elevated pulmonary artery pressure, which can lead to right heart failure and death if untreated [2] Group 2 - Symptoms of PAH are non-specific and may include shortness of breath after activity, cyanosis (blue lips) due to chronic hypoxia, decreased appetite, abdominal bloating, and edema in the lower limbs [4][5][6] - Severe cases may also present with hair loss, photosensitivity, oral ulcers, and arthritis [6] Group 3 - Prevention strategies for PAH include avoiding prolonged sitting to prevent deep vein thrombosis, which can lead to pulmonary embolism and subsequently PAH [12] - Smoking cessation is crucial as it damages pulmonary vascular endothelial cells, increasing the risk of PAH [13] - Regular health check-ups are important for high-risk individuals, such as those with a family history of PAH or related underlying conditions, to detect early signs of the disease [15]